BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pathology News - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pathology News
X-ORIGINAL-URL:https://www.pathologynews.com
X-WR-CALDESC:Events for Pathology News
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20260408T160000
DTEND;TZID=UTC:20260408T170000
DTSTAMP:20260828T112044
CREATED:20260402T161306Z
LAST-MODIFIED:20260402T161306Z
UID:100120087-1775664000-1775667600@www.pathologynews.com
SUMMARY:Advancing Imaging Interoperability Together: A DPA-CAP-SIIM Collaboration to Improve Standardized Workflow Adoption
DESCRIPTION:0000Days00Hrs00Min00SecOverviewInteroperability across medical imaging is no longer optional—it is foundational to the future of connected\, scalable\, and patient-centered care. In this webinar\, we will review results from the recent SIIM-DPA-CAP DICOM Toolkit Survey and discuss what they reveal about the current state of standards adoption in digital pathology. Additionally\, the session will examine the critical role of DICOM and IHE in supporting consistent imaging metadata and enabling interoperability across pathology\, radiology\, and other imaging-rich specialties. A panel featuring representatives from DPA\, CAP\, SIIM and pathologists with standards based interoperability\, including deployment for clinical use\, will share perspectives on current challenges\, emerging opportunities\, and the importance of coordinated action. \nLearning ObjectivesBy the end of this webinar\, participants will be able to: \n\nSummarize the key findings of the recent DICOM Toolkit Survey and their implications for standards adoption and interoperability in medical imaging.\nDescribe the importance of DICOM and IHE standards in supporting consistent\, interoperable imaging metadata across pathology\, radiology\, and other imaging domains.\nDiscuss the role of DPA in accelerating cross-organizational collaboration in advancing practical interoperability for clinical care\, operations\, and innovation.\n\nRegister NowPresentersAlexander Towbin\, MD\, FAAP\, FACR\, FSIIM\, FICIS\nCincinnati Children’s Hospital Medical Center \nAlexander J. Towbin\, MD is Professor of Radiology and the Neil D. Johnson Chair of Radiology Informatics at Cincinnati Children’s Hospital Medical Center. He also serves as Associate Chief of Radiology\, Associate Chief Medical Information Officer\, and Associate Chief of Staff. Internationally recognized for advancing pediatric radiology\, imaging informatics\, and quality improvement\, he brings particular expertise in abdominal and cancer imaging and in the use of imaging data to improve clinical care and interoperability across the healthcare enterprise. \nA prolific scholar and educator\, Dr. Towbin has delivered invited lectures worldwide and published more than 400 manuscripts and 150 book chapters. He currently serves as Chair-Elect of the Society for Imaging Informatics in Medicine and previously served as co-chair of the HIMSS–SIIM Enterprise Imaging Community. His work bridges clinical care\, research\, and informatics to improve outcomes for children\, families\, and the healthcare workforce. \nKevin Schap\, MScBMI\nDirector of Clinic Informatics\, Digital Pathology\, and Data Science\nCollege of American Pathologists \nKevin Schap\, MScBMI\, is Director of Clinical Informatics\, Digital Pathology\, and Data Science at the College of American Pathologists. He specializes in advancing digital pathology standards\, with expertise in DICOM whole slide imaging (WSI) and IHE Pathology and Laboratory Medicine (PaLM) interoperability frameworks. Kevin oversees multiple CAP initiatives\, including the AI Committee\, Digital and Computational Pathology Committee\, Informatics Committee\, and the Council on Informatics and Pathology Innovation. His work focuses on accelerating standards adoption and developing educational strategies that empower pathologists to effectively evaluate and integrate artificial intelligence tools into clinical practice. \nMustafa Yousif\, MD\nUniversity of Michigan \nDr. Mustafa Yousif is the Associate Chief Medical Information Officer\, Associate Director of Pathology Informatics\, Assistant Professor of Pathology Informatics\, and Medical Director of Digital Pathology at the University of Michigan. He completed his anatomical and clinical pathology residency at Wake Forest University\, followed by fellowships in Gynecologic and Breast Pathology at the University of Pittsburgh Medical Center and Pathology Informatics at the University of Michigan. Dr. Yousif serves as Co-chair of DICOM WG-26: Pathology. His research focuses on digital pathology\, artificial intelligence\, computer vision\, and image analysis\, alongside gynecologic and breast pathology. \nModeratorsJohn Groth\, MD\, Pathologist\,Endeavor Health \nJennifer Samboy\, MHA\, Digital Transformation Leader\, Philips Digital & Computational Pathology
URL:https://www.pathologynews.com/event/advancing-imaging-interoperability-together-a-dpa-cap-siim-collaboration-to-improve-standardized-workflow-adoption/
LOCATION:Online
CATEGORIES:Live Online Webinar
ATTACH;FMTTYPE=image/jpeg:https://www.pathologynews.com/wp-content/uploads/2026/04/Advancing-Imaging-Interoperability-Together-A-DPA-CAP-SIIM-Collaboration-to-Improve-Standardized-Workflow-Adoption.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260409T150000
DTEND;TZID=Europe/London:20260409T160000
DTSTAMP:20260828T112044
CREATED:20260310T104319Z
LAST-MODIFIED:20260310T154422Z
UID:100119214-1775746800-1775750400@www.pathologynews.com
SUMMARY:From Research to Routine: High-Throughput Spatial Biology with ZEISS and Mindpeak
DESCRIPTION:0000Days00Hrs00Min00SecAs the demand for complex biomarker analysis and precision oncology grows\, organizations face significant hurdles in scaling multiplex immunofluorescence (mIF) and spatial biology for high-throughput production. Traditional spatial workflows are often fragmented\, relying on manual processes and complex image analysis pipelines that require hundreds of hours of training and specialized bioinformatics expertise. \nIn this webinar\, we explore how to eliminate these bottlenecks and transition spatial biology from a low-throughput research tool into a robust\, production-ready environment that delivers images in and results out. We will dive into the integrated\, end-to-end solution developed by ZEISS and Mindpeak\, designed to seamlessly connect reagents\, high-speed scanning\, and automated image analysis. Attendees will learn how the ZEISS AxioScan 7 Spatial Biology enables standardized\, clinical-routine-ready imaging capable of processing up to 100 slides per day. \nFurthermore\, we will demonstrate how Mindpeak’s PhenoScout AI provides a “Turn-key” analysis experience\, allowing users to bypass months of algorithm training and achieve expert-grade\, single-cell precision without requiring any prior image analysis expertise. \nJoin us to discover how this seamless integration minimizes data handling complexities\, accelerates time-to-insight\, and ultimately establishes a reliable pathway from translational research and clinical trials to future diagnostic assays. \nLearning Objectives\n\nIdentify key hurdles of bringing mIF/spatial biology into high-throughput production.\nDiscuss solutions on the reagents\, scanner\, workflow\, and image analysis parts of the workflow\, with an emphasis on PhenoScout by Mindpeak.\nEvaluate the requirements for transitioning from manual research protocols to clinical-routine-ready imaging ecosystems.\n\nWhat We Will Cover\n\nHigh-Throughput Imaging: How the ZEISS AxioScan 7 enables standardized\, clinical-grade imaging for up to 100 slides per day.\nTurn-key AI Analysis: How Mindpeak’s PhenoScout AI provides expert-grade\, single-cell precision without requiring prior image analysis or algorithm training.\nClinical Pathways: How this integration minimizes data handling\, accelerates time-to-insight\, and establishes a reliable path from research to future diagnostic assays.\n\nKey Takeaways\n\nSpatial biology is now ready for production: Organizations can finally scale complex spatial workflows without sacrificing speed or reliability.\nUnlocking Massive Scale and Reliability (ZEISS Advantage): Achieve unprecedented throughput and standardization. By providing a highly reproducible\, clinical-routine-ready imaging ecosystem\, ZEISS allows labs to confidently process up to 100 slides per day\, establishing a clear pathway from translational research to regulatory clearance.\nEliminating the Analysis Bottleneck (Mindpeak Advantage): Experience “Zero Friction” spatial analysis. Mindpeak’s clinically validated AI completely removes the need for specialized bioinformatics expertise or months of software training. Users get immediate\, expert-grade precision\, freeing them to focus entirely on actionable biology rather than managing complex IT infrastructure.\nA Seamless\, End-to-End Clinical Pathway: Together\, ZEISS and Mindpeak deliver a fully automated\, end-to-end solution. From standardized high-quality image acquisition to instant\, reproducible biomarker reporting\, the integrated workflow minimizes data handling complexities and accelerates time-to-insight for high-throughput clients.\nReduced Operational Overhead: Automation of both hardware and software steps significantly lowers the cost-per-slide and reduces human error\, making spatial biology a viable option for large-scale clinical trials.\nStandardization for Future Diagnostics: This integrated approach provides the data consistency and quality control necessary to move biomarkers from the discovery phase toward validated clinical assays.\n\nRegister NowSpeakers\nDr. Moritz Widmaier \nExpert in Spatial Biology & Digital Pathology \nZEISS Research Microscopy Solutions \nDr. Moritz Widmaier is a recognized leader in spatial biology\, digital pathology\, and biomarker data analytics. Currently at ZEISS Research Microscopy Solutions\, he drives innovation in spatial biology workflows\, focusing on automation\, AI-powered image analysis\, and advanced imaging solutions like the ZEISS Axioscan 7 spatial Biology. \nWith a Ph.D. in Biochemistry and a unique ability to bridge the gap between complex biology and data science\, Dr. Widmaier has a proven track record of developing cutting-edge AI and data analytics products. Prior to ZEISS\, he held pivotal scientific and product leadership roles at industry-leading companies\, including Definiens\, AstraZeneca and Ultivue. \nHis extensive expertise spans across (immuno-) oncology\, multiplex immunofluorescence reagent chemistry and assay development and machine learning. Today\, Dr. Widmaier specializes in helping researchers leverage automated imaging and AI to turn intricate spatial data into reproducible\, actionable clinical and research insights. \nDr. Fabian Schneider \nSenior Product Manager \nMindpeak \nFabian Schneider\, PhD\, is Senior Product Manager at Mindpeak\, where he shapes the development and delivery of AI solutions for pathology. He has more than a decade of experience across leading organisations in computational pathology\, oncology and biomarker research. His career has spanned both scientific and product leadership\, from contributing to the establishment of automated data reporting for digital pathology assay data supporting clinical oncology studies at Roche\, to advancing computational pathology pipelines at AstraZeneca and leading product development for research solutions at Visiopharm. \nWith a doctorate from the University Hospital Frankfurt focused on Wnt signalling in tumour formation and angiogenesis\, followed by postdoctoral research at the Karolinska Institutet and the Technical University of Munich\, Dr. Schneider combines scientific depth with hands-on experience in product strategy and clinical translation. At Mindpeak\, he draws on this background to guide the development of AI tools that are scientifically robust\, clinically relevant and aligned with the needs of pathologists worldwide.
URL:https://www.pathologynews.com/event/from-research-to-routine-high-throughput-spatial-biology-with-zeiss-and-mindpeak/
LOCATION:Online
CATEGORIES:Live Online Webinar,PN Webinar
ATTACH;FMTTYPE=image/png:https://www.pathologynews.com/wp-content/uploads/2026/03/min-web0-assets.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260413T143000
DTEND;TZID=Europe/London:20260413T153000
DTSTAMP:20260828T112044
CREATED:20260323T132633Z
LAST-MODIFIED:20260323T132633Z
UID:100119823-1776090600-1776094200@www.pathologynews.com
SUMMARY:SAGE: Agentic Framework for Interpretable and Clinically Translatable Computational Pathology Biomarker Discovery
DESCRIPTION:0000Days00Hrs00Min00SecThe Tissue Image Analytics (TIA) Centre hosts a seminar series for those interested in computational pathology. The series invites researchers and leaders in computational pathology and related fields to present their work and foster thought-provoking discussions. \nThis seminar features Dr Sahar Almahfouz Nasser from Emory University\, USA. \nAbstract\nDespite significant progress in computational pathology\, many AI models remain black-box and difficult to interpret\, posing a major barrier to clinical adoption due to limited transparency and explainability. This has motivated continued interest in engineered image-based biomarkers\, which offer greater interpretability but are often proposed based on anecdotal evidence or fragmented prior literature rather than systematic biological validation. We introduce SAGE (Structured Agentic system for hypothesis Generation and Evaluation)\, an agentic AI system designed to identify interpretable\, engineered pathology biomarkers by grounding them in biological evidence. SAGE integrates literature-anchored reasoning with multi-modal data analysis to correlate image-derived features with molecular biomarkers\, such as gene expression\, and clinically relevant outcomes. By coordinating specialized agents for biological contextualization and empirical hypothesis validation\, SAGE prioritizes transparent\, biologically supported biomarkers and advances the clinical translation of computational pathology. \nRegister NowBio\nDr. Sahar Almahfouz Nasser is a postdoctoral researcher at Emory University’s Madabhushi Lab\, working at the intersection of computational pathology\, agentic AI\, and translational oncology. She is the creator of SAGE\, an agentic framework for biologically grounded and clinically translatable biomarker discovery\, with a focus on interpretable and trustworthy AI for cancer care. She is a recipient of the Qualcomm Innovation Fellowship\, and her work has been published in leading AI and medical imaging venues.
URL:https://www.pathologynews.com/event/sage-agentic-framework-for-interpretable-and-clinically-translatable-computational-pathology-biomarker-discovery/
LOCATION:Online
CATEGORIES:Live Online Webinar
ATTACH;FMTTYPE=image/png:https://www.pathologynews.com/wp-content/uploads/2026/03/TIA-Centre-Seminar-Series-SAGE-Agentic-Framework-for-Interpretable-and-Clinically-Translatable-Computational-Pathology-Biomarker-Discovery.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260416T160000
DTEND;TZID=UTC:20260416T170000
DTSTAMP:20260828T112044
CREATED:20260302T141300Z
LAST-MODIFIED:20260302T141300Z
UID:100119058-1776355200-1776358800@www.pathologynews.com
SUMMARY:HALO AP 2.5 Sneak Peek Webinar
DESCRIPTION:0000Days00Hrs00Min00SecThe webinar starts at 8:00 PDT\, 11:00 EDT\, 16:00 BST \nLearn about the exciting new features in the 2.5 versions of HALO AP®!\n\n  \n\nSummary\n\n\n\n\nJoin us for a 1-hour webinar showcasing the latest advancements in HALO AP® version 2.5. Our robust digital pathology platform has been enhanced to support multi-site deployments\, new tools for the pathologist\, enhanced toolkit for collaboration\, and new Lab Logic capabilities. Hallie Rane\, Associate Product Manager for Clinical Applications at Indica Labs\, will demonstrate HALO AP’s Lab Logic capabilities\, highlighting recent improvements and exciting new features that make it easier to configure workflows combining AI results\, rules\, thresholds\, and manual review steps. Lab Logic brings these elements together in a single\, cohesive model\, giving labs more control over how decisions are made and actions are triggered across the platform.  \nHallie will also highlight updates to the tumor board module version 2.0 and show attendees how the new tumor board features support complex diagnostics when multi-disciplinary collaboration is key. Hallie will also give a detailed overview of additional HALO AP 2.5 features which include robust functionality and improved support for multi-site institutions including smart slide lists and profiles; site-specific reporting on a single platform; secondary assignee workflows; and multi-specimen support for a truly comprehensive bench-to-bedside workflow.  \n\n\n\n  \n\n\nLearning Objectives\n\n\n\n\n\nUnderstand the functionality of the HALO AP®platform and how it supports image and case management in anatomic pathology.\nUnderstand how Lab Logic provides a unified way to define\, manage and automate workflow behavior across AI and manual processes.\nDiscover new and improved collaboration tools for support of complex diagnostics and multi-disciplinary team meetings and learn how these new features support large medical institutions and multi-site deployments.\nIdentify how the new features in HALO AP 2.5 work together to create a configurable\, fully automatic\, AI-ready workflow for bench-to-bedside support. \n\n\n\nHALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe\, the UK\, and Switzerland. HALO AP® is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use. In addition\, HALO AP® provides built-in compliance with FDA 21 CFR Part 11\, HIPAA\, and GDPR. WBS-MAR-000020v1 \n\nRegister Now\nPresenter\n\nHallie RaneAssociate Product Manager for Clinical Applications Indica Labs  \nHallie Rane received a BS in biology from the University of New Mexico and has a background in molecular biology and evolution. Hallie joined Indica Labs in 2023 as the Product Specialist for HALO AP. Prior to Indica Labs\, Hallie worked in both industry and academic positions and has held a variety of technical and customer-facing roles\, where she collaborated with customers\, scientists\, and technicians to develop a diverse array of products. Her journey encompassed ventures into biotechnology innovation\, academic research labs\, and even the realm of craft beer production\, where she served as Head Brewer. 
URL:https://www.pathologynews.com/event/halo-ap-2-5-sneak-peek-webinar/
LOCATION:Online
CATEGORIES:Live Online Webinar
ATTACH;FMTTYPE=image/jpeg:https://www.pathologynews.com/wp-content/uploads/2026/03/HALO-AP-webinar_800x600.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260416T160000
DTEND;TZID=Europe/London:20260416T170000
DTSTAMP:20260828T112044
CREATED:20260402T132342Z
LAST-MODIFIED:20260402T132342Z
UID:100120080-1776355200-1776358800@www.pathologynews.com
SUMMARY:Why Aiforia’s Foundation Engine is Advancing Digital Pathology
DESCRIPTION:0000Days00Hrs00Min00SecThis webinar will start at 5 pm CEST\, 6 pm EEST\, 11 am pm EDT \nAI model development used to be a marathon of data and time\, but we have built a shortcut. Join Aiforia’s CPO and Director of Software Development to discover how Aiforia’s Foundation Engine elevates your research and diagnostics. \nThis session explores the design principles of Aiforia’s Foundation Engine and explains how this patent-pending technology sets a new benchmark for high-performance pixel-level image analysis and clinical-grade quality. \nPanu Kauppila\, M.Sc. (Tech.)\, Aiforia’s Chief Product Officer\, together with Yrjö Häme\, Ph.D.\, Aiforia’s Director of Software Development\, explain how pre-trained foundation models reduce AI model development timelines\, improve robustness\, and\, when combined with pathologists’ task-specific annotations\, provide even greater precision in clinical workflows. They will dive into Foundation Engine’s unparalleled technological architecture and capabilities\, enabling faster development and better generalization than with models based on convolutional neural networks. \nWhat will the session cover\n\nTechnology: analyzing the “under the hood” mechanics that power the Foundation Engine\nBenefits: maximizing AI model development throughput and expert-level precision with significantly less training data and manual effort while remaining cost-effective\nIntegration: how to access and deploy Foundation Models within the platform\nPractical examples: real-world use cases and performance results in Aiforia.\n\nWho should join?\n\nClinical pathologists seeking more robust and transparent AI tools\nDigital pathology innovators looking for the ultimate shortcut to high-performance AI models\nResearchers aiming to scale their throughput with less training data\nLab directors and managers aiming to increase diagnostic throughput and ensure reproducibility across clinical workflows\n\nRegister NowPresenters\nPanu Kauppila\, M.Sc. (Tech.)\nChief Product Officer\nAiforia \nPanu Kauppila is the Chief Product Officer (CPO) of Aiforia\, playing a key role in defining Aiforia’s product portfolio and prioritizing product development. He has more than 25 years of experience in productization and management of innovation in the medical technology sector in international companies. Thus\, Panu has a profound understanding of how\, with strong technological expertise\, scalable products can be built on top of a software platform for demanding preclinical and clinical use. He holds an M.Sc. in Physics and Medical Technology. \nYrjö Häme\, Ph.D.\nDirector of Software Development\nAiforia \nPanu Kauppila is the Chief Product Officer (CPO) of Aiforia\, playing a key role in defining Aiforia’s product portfolio and prioritizing product development. He has more than 25 years of experience in productization and management of innovation in the medical technology sector in international companies. Thus\, Panu has a profound understanding of how\, with strong technological expertise\, scalable products can be built on top of a software platform for demanding preclinical and clinical use. He holds an M.Sc. in Physics and Medical Technology.
URL:https://www.pathologynews.com/event/why-aiforias-foundation-engine-is-advancing-digital-pathology/
LOCATION:Online
CATEGORIES:Live Online Webinar
ATTACH;FMTTYPE=image/jpeg:https://www.pathologynews.com/wp-content/uploads/2026/04/Why-Aiforias-Foundation-Engine-is-Advancing-Digital-Pathology.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260427T140000
DTEND;TZID=Europe/London:20260427T150000
DTSTAMP:20260828T112044
CREATED:20260323T133351Z
LAST-MODIFIED:20260323T133351Z
UID:100119827-1777298400-1777302000@www.pathologynews.com
SUMMARY:Foundation Models in Oncology: Why Benchmark Success Does Not Translate to Clinical Practice
DESCRIPTION:0000Days00Hrs00Min00SecThe Tissue Image Analytics (TIA) Centre hosts a seminar series for those interested in computational pathology. The series invites researchers and leaders in computational pathology and related fields to present their work and foster thought-provoking discussions. \nThis seminar features Dr Duan Zhiyun from Fudan University\, China. \nAbstract\nFoundation models are rapidly reshaping biomedical research and hold great promise for oncology. Yet despite impressive benchmark performance\, their impact in real clinical settings remains limited. A key reason is that most current models are designed as narrow specialists optimized for static tasks\, while clinical oncology requires more generalist systems. Effective clinical support demands models that can integrate multimodal information\, follow the longitudinal course of disease\, and incorporate patient perspectives into decision-making. Rethinking model design along these dimensions will be crucial if foundation models are to move beyond benchmarks and become trusted partners in cancer care. \nRegister NowBio\nDuan is a medical doctor at Zhongshan Hospital of Fudan University\, Shanghai\, China. He has published as first author in several great journals in medicine\, including Cell Reports Medicine\, Nature Cancer\, and Journal of Translational Medicine over the past three years.
URL:https://www.pathologynews.com/event/foundation-models-in-oncology-why-benchmark-success-does-not-translate-to-clinical-practice/
LOCATION:Online
CATEGORIES:Live Online Webinar
ATTACH;FMTTYPE=image/png:https://www.pathologynews.com/wp-content/uploads/2026/03/TIA-Centre-Seminar-Series-Foundation-Models-in-Oncology-Why-Benchmark-Success-Does-Not-Translate-to-Clinical-Practice.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260428T160000
DTEND;TZID=Europe/London:20260428T170000
DTSTAMP:20260828T112044
CREATED:20260416T091002Z
LAST-MODIFIED:20260416T093435Z
UID:100120322-1777392000-1777395600@www.pathologynews.com
SUMMARY:Inside Concentriq: The Product Behind the Top KLAS Score
DESCRIPTION:0000Days00Hrs00Min00SecThe webinar will start at 11am ET\, 4pm BST \nDigital Pathology Built for Real-World Practice\nAs digital pathology moves into daily practice\, the standard for what a platform should deliver is rising: an experience that works the way pathologists think\, operations that grow with the lab\, and AI that fits naturally into the workflow. \nProscia built Concentriq to that standard\, and continues to evolve it alongside the customers who use it every day. As a result\, Proscia’s customers told KLAS they trust Concentriq\, rating Proscia the top-performing digital pathology vendor across the US¹ and Europe.² \nJoin Proscia’s product team for a look at how the platform works in practice across academic medical centers\, health systems\, and reference labs — and a sneak peek at what we’re building next. Plus\, you’ll hear from guest speaker Daniel Roberts\, MD\, Medical Director of Digital Pathology at Cleveland Clinic\, on what digital pathology adoption and change management actually looks like in practice at one of the nation’s largest academic medical centers. \nRecommended for: Pathology leaders\, laboratory operations teams\, IT and informatics professionals\, and digital pathology leaders evaluating or expanding digital pathology programs. \nRegister NowPresenters\n\nDr. Daniel Roberts\nMedical Director of Digital Pathology\nCleveland Clinic\n\nAmanda Coble\nSenior Director of Product\nProscia\n\nPradyuman Kodavatiganti\nSenior Product Designer\nProscia\n\n\nAshley Faber\nSenior Director of Product Marketing\nProscia
URL:https://www.pathologynews.com/event/inside-concentriq-the-product-behind-the-top-klas-score/
LOCATION:Online
CATEGORIES:Live Online Webinar
ATTACH;FMTTYPE=image/jpeg:https://www.pathologynews.com/wp-content/uploads/2026/04/Inside-Concentriq-The-Product-Behind-the-Top-KLAS-Score.jpg
END:VEVENT
END:VCALENDAR